Use of recombinant human erythropoietin outside the setting of uremia.
Cazzola
M
M
Department of Internal Medicine and Medical Therapy, IRCCS Policlinico San Matteo and University of Pavia Medical School, Italy.
Mercuriali
F
F
Brugnara
C
C
D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D016063:Blood Loss, Surgical; D001804:Blood Transfusion, Autologous; D003362:Cost-Benefit Analysis; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000096:biosynthesis / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D005246:Feedback; D006402:Hematologic Diseases / Q000150:complications / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D000090463:Iron Deficiencies; D007668:Kidney / Q000378:metabolism; D009369:Neoplasms / Q000150:complications; D011994:Recombinant Proteins; D014511:Uremia
D011994:Recombinant Proteins; D004921:Erythropoietin